<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117546">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01743469</url>
  </required_header>
  <id_info>
    <org_study_id>8-55-58102-004</org_study_id>
    <nct_id>NCT01743469</nct_id>
  </id_info>
  <brief_title>A Study With Tasquinimod Treating Patients in Four Independent Cohorts of Hepatocellular, Ovarian, Renal Cell and Gastric Cancers</brief_title>
  <official_title>A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory proof of concept study to determine the clinical activity of
      tasquinimod in patients with advanced or metastatic hepatocellular carcinoma (Cohort H),
      ovarian carcinoma (Cohort O), renal cell carcinoma (Cohort R) and gastric carcinoma (Cohort
      G) who have progressed after standard therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical activity of tasquinimod will be evaluated independently in each individual
      cohort of patients of the four different tumour types, namely Cohort H, Cohort O, Cohort R
      and Cohort G respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival [PFS] rate, defined as the proportion of patients who have neither progressed nor died as measured by RECIST v1.1 (both Cohorts H and R)</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival [PFS] rate, defined as the proportion of patients who have neither progressed nor died as measured by RECIST v1.1 (Cohort G)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival [PFS] rate, defined as the proportion of patients who have neither progressed nor died as measured by RECIST v1.1 (Cohort O)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate, defined by RECIST v1.1 (Cohorts H, R and O) and Choi criteria (Cohort H)</measure>
    <time_frame>Every 8 weeks until disease progression, up to 45 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate, defined by RECIST v1.1 (Cohort G)</measure>
    <time_frame>Every 6 weeks until disease progression, up to 45 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit (Cohorts H, R and O)</measure>
    <time_frame>Every 8 weeks until disease progression, up to 45 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical benefit defined as complete response + partial response + stable disease lasting at least 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit (Cohort G)</measure>
    <time_frame>Every 6 weeks until disease progression, up to 45 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical benefit defined as complete response + partial response + stable disease lasting at least 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression Free Survival (PFS), (Cohorts H, R and O)</measure>
    <time_frame>Every 8 weeks until disease progression, up to 45 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS defined as the time from first study treatment to progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression Free Survival (PFS), (Cohort G)</measure>
    <time_frame>Every 6 weeks until disease progression, up to 45 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS defined as the time from first study treatment to progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP), (Cohorts H, R and O)</measure>
    <time_frame>Every 8 weeks until disease progression, up to 45 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>TTP defined as the time from first study treatment to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP), (Cohort G)</measure>
    <time_frame>Every 6 weeks until disease progression, up to 45 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>TTP defined as the time from first study treatment to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS), defined as the time from first study treatment to death due to any cause.</measure>
    <time_frame>Time from first study treatment to death, up to 45 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Advanced or Metastatic Hepatocellular Cancer</condition>
  <condition>Advanced or Metastatic Ovarian Cancer</condition>
  <condition>Metastatic Renal Cell Cancer</condition>
  <condition>Advanced or Metastatic Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>Tasquinimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, unacceptable toxicity or willingness to stop.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tasquinimod</intervention_name>
    <arm_group_label>Tasquinimod</arm_group_label>
    <other_name>1 capsule:initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5mg/day or decreasing to 0.25mg after at least 2 weeks.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic or advanced hepatocellular carcinoma, Barcelona
             Clinic Liver Cancer stage C or B not amenable to locoregional therapy or refractory
             to locoregional therapy, Child-Pugh A, previously treated by sorafenib

          -  Histologically confirmed metastatic or advanced ovarian epithelial, fallopian tube or
             primary peritoneal cavity cancer, progression within 6 months of a platinum
             containing chemotherapy regimen

          -  Histologically confirmed metastatic renal cell cancer, previously treated with at
             least one vascular endothelial growth factor (VEGF) inhibitor, at most two prior
             targeted therapies

          -  Histologically confirmed metastatic or advanced gastric cancer after one line of
             chemotherapy containing platinum and fluoropyrimidine

        Exclusion Criteria:

          -  Other primary malignancy within the past 3 years (except for fully resected non
             melanoma skin cancer, localised prostate cancer with normal prostate specific antigen
             level, or cervical cancer in situ)

          -  Malabsorption (other than in Cohort G patients and partial or complete gastrectomy)
             or intestinal obstruction

          -  History of pancreatitis

          -  History of myocardial infarction, unstable angina, congestive heart failure New York
             Heart Association class III/IV, cerebrovascular accident, transient ischaemic attack,
             limb claudication at rest in the previous 6 months, or ongoing symptomatic
             dysrhythmias, or uncontrolled atrial, or ventricular arrhythmias, or uncontrolled
             hypertension defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure
             ≥90 mmHg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie GERMANN, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antwerp University Hospital, Wilrijkstraat 10</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital, 1K12 IE, De Pintelaan 185</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leuven cancer institute (LKI), Herestraat</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre, 699 Concession St</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center, 790 Commissoners Road East</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Credit Valley Hospital and Trillium Health Centre, 2200 Eglinton Ave. West</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret, 610 University Avenue</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook, 2075 Bayview Avenue, Suite T2049</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center, 2210-2nd Street SW</name>
      <address>
        <city>Calgary</city>
        <zip>T2S 3C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHUM, Hopital Notre Dame, 1560 Sherbrooke Street East</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Quebec, 11 Cote du Palais</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Beaujon, 100 Blvd du Général Leclerc</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret, 3 rue Frédéric Combemale</name>
      <address>
        <city>Lille cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Bureau d'Etudes Cliniques du Centre Léon Bérard, 28, rue Laennec</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges-Pompidou, AP-HP, 20 Rue Leblanc</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Saint-Antoine, 184 rue du Faubourg St Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis, Avenue bataille Flandres Dunkerque</name>
      <address>
        <city>Rennes cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau, Boulevard Jacques Monod</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute Gustave-Roussy, 114 rue Edouard Vaillant</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del mar, Paseo Maritimo 25-29</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Centre, Ctra. Colmenar Viejo Km. 9 100,</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon, Dr. Esquerdo, 44-46</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ La Paz, Paseo Castellana 261</name>
      <address>
        <city>Madrid</city>
        <zip>28045</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre, 1053 Great Western Road</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital, Gwndolen Road</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital, Downs Rd, Sutton</name>
      <address>
        <city>London</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital, Wilmslow Road, Withington</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital, Freeman Road, High Heaton</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital, Tremona Road, Shirley</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>November 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
